The pharmacokinetics and pharmacodynamics of iron preparations.
Article Details
- CitationCopy to clipboard
Geisser P, Burckhardt S
The pharmacokinetics and pharmacodynamics of iron preparations.
Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012.
- PubMed ID
- 24310424 [ View in PubMed]
- Abstract
Standard approaches are not appropriate when assessing pharmacokinetics of iron supplements due to the ubiquity of endogenous iron, its compartmentalized sites of action, and the complexity of the iron metabolism. The primary site of action of iron is the erythrocyte, and, in contrast to conventional drugs, no drug-receptor interaction takes place. Notably, the process of erythropoiesis, i.e., formation of new erythrocytes, takes 3-4 weeks. Accordingly, serum iron concentration and area under the curve (AUC) are clinically irrelevant for assessing iron utilization. Iron can be administered intravenously in the form of polynuclear iron(III)-hydroxide complexes with carbohydrate ligands or orally as iron(II) (ferrous) salts or iron(III) (ferric) complexes. Several approaches have been employed to study the pharmacodynamics of iron after oral administration. Quantification of iron uptake from radiolabeled preparations by the whole body or the erythrocytes is optimal, but alternatively total iron transfer can be calculated based on known elimination rates and the intrinsic reactivity of individual preparations. Degradation kinetics, and thus the safety, of parenteral iron preparations are directly related to the molecular weight and the stability of the complex. High oral iron doses or rapid release of iron from intravenous iron preparations can saturate the iron transport system, resulting in oxidative stress with adverse clinical and subclinical consequences. Appropriate pharmacokinetics and pharmacodynamics analyses will greatly assist our understanding of the likely contribution of novel preparations to the management of anemia.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Ferric cation Transferrin receptor protein 1 Protein Humans YesAgonistDetails Ferric derisomaltose Hemoglobin subunit alpha Protein Humans UnknownBinderDetails Ferric derisomaltose Transferrin receptor (Protein Group) Protein group Humans UnknownBinderDetails Ferrous sulfate anhydrous Hemoglobin subunit alpha Protein Humans YesBinderDetails Ferrous sulfate anhydrous Transferrin receptor (Protein Group) Protein group Humans YesSubstrateDetails Tetraferric tricitrate decahydrate Transferrin receptor protein 1 Protein Humans YesLigandDetails - Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Ferrous sulfate anhydrous Cytochrome b reductase 1 Protein Humans UnknownSubstrateDetails Ferrous sulfate anhydrous Serotransferrin Protein Humans UnknownSubstrateDetails - Drug Transporters
Drug Transporter Kind Organism Pharmacological Action Actions Ferrous sulfate anhydrous Natural resistance-associated macrophage protein 2 Protein Humans UnknownSubstrateDetails - Drug Reactions
Reaction Details
